Dr. Adam Goulburn serves as Partner at Lux Capital. He serves as Board Member at Eikon Therapeutics, Plexium and Mahana Therapeutics. He also serves as Board Member at Atavistik Bio. He served as Board member at Kallyope. He is based in the firm's New York headquarters and focuses on broad investment opportunities in healthcare IT, services, mobile health, and therapeutics. He was a Board Member of Authorea, Variant Bio & 3Scan. He has worked extensively with a number of Lux portfolio companies including Kala Pharmaceuticals and Genocea Biosciences. He is also a mentor for healthcare IT incubators Blueprint Health and Healthbox. Before joining Lux, he was a Postdoctoral Fellow of Neuroscience at Weill Cornell Medical College, researching regenerative medicine in association with brain disorders including schizophrenia and Alzheimer's disease. Originally from Australia, he has dual undergraduate degrees in Commerce and Science and subsequently completed his Ph.D. at the Australian Stem Cell Centre, having been chosen as a highly selective Premier Scholar. He has published in numerous peer-reviewed scientific journals. Prior to joining Lux in 2011, he received his Ph.D. in neuroscience from Weill Cornell Medical College. He also serves as Board Member at Vesta Healthcare. He serves as Board Member at Rivet Health and rd. MD. He is a Co-Founder of Cajal Neuroscience.